Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation

• DOI: 10.1136/jitc-2020-001403
• Publication Date: 2020-10-19T21:30:49Z
• Authors: Alessio Cortellini; Biagio Ricciuti; Marcello Tiseo; Emilio Bria; Giuseppe L Banna; Joachim GJV Aerts; Fausto Barbieri; Raffaele Giusti; Diego L Cortinovis; Maria R Migliorino; Annamaria Catino; Francesco Passiglia; Mariangela Torniai; Alessandro Morabito; Carlo Genova; Francesca Mazzoni; Vincenzo Di Noia; Diego Signorelli; Alain Gelibter; Mario Alberto Occ...; Francesca Rastelli; Rita Chiari; Danilo Rocco; Alessandro Inno; Michele De Tursi; Pietro Di Marino; Giovanni Mansueto; Federica Zoratto; Francesco Grossi; Marco Filetti; Pamela Pizzutilo; Marco Russano; Fabrizio Citarella; Luca Cantini; Giada Targato; Olga Nigro; Miriam G Ferrara; Sebastiano Buti; Simona Scodes; Lorenza Landi; Giorgia Guaitoli; Luigi Della Gravara; Fabrizio Tabbò; Serena Ricciardi; Alessandro De Toma; Alex Friedlaender; Fausto Petrelli; Alfredo Addeo; Giampiero Porzio; Corrado Ficorella
• Keywords: Adult; Male; Lung Neoplasms; immunotherapy; cell lung-cancer; body-mass index; clinical-outcomes; association; survival; 610; Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Body Mass Index; immunotherapy, non-small cell lung cancer, obesity; 03 medical and health sciences; 0302 clinical medicine; immunotherapy; oncology; Carcinoma, Non-Small-Cell Lung; 616; Humans; Obesity; immunotherapy;; RC254-282; Aged; Clinical/Translational Cancer Immunotherapy; Aged, 80 and over; 2. Zero hunger; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; Middle Aged; EMC MM-04-42-02; 3. Good health; Female; immunotherapy

Background The association between obesity and outcomes in patients receiving programmed death-1/programmed death ligand-1 (PD-L1) checkpoint inhibitors has already been confirmed pre-treated non-small cell lung cancer (NSCLC) patients, regardless of PD-L1 tumor expression. Methods We present the analysis according to baseline body mass index (BMI) BMI variation a large cohort metastatic NSCLC with expression ≥50%, first line pembrolizumab. also evaluated control treated platinum-based chemotherapy. Normal weight was set as group. Results 962 426 were included pembrolizumab chemotherapy cohorts, respectively. Obese had significantly higher objective response rate (ORR) (OR=1.61 (95% CI: 1.04–2.50)) cohort, while overweight lower ORR (OR=0.59 0.37–0.92)) within cohort. longer progression-free survival (PFS) (HR=0.61 0.45–0.82)) Conversely, they shorter PFS (HR=1.27 1.01–1.60)). overall (OS) (HR=0.70 0.49–0.99)), no significant differences found affected ORR, OS both cohorts. Conclusions Baseline is associated improved pembrolizumab, but not among related clinical outcomes.